Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus has entered into an agreement with an Alcon Biomedical Research Unit, ESBATech for the development of a controlled release formulation for one of its proprietary biological compounds for ophthalmic applications.
Subscribe to our email newsletter
The agreement includes process development, scale-up and manufacturing for pre-clinical studies.
OctoPlus evaluated the feasibility of a controlled release formulation that combines a proprietary eye care ingredient of ESBATech with PolyActive.
OctoPlus CEO Jan Egberts said he is delighted to see the success of the technology further validated in a product from ESBATech.
"In addition to Locteron, this programme is now next in line in the commercialisation of the PolyActive controlled release technology," Egberts said.